Why the study?
Does antiplatelet therapy reduce cardiovascular events and mortality in patients with diabetes?
Does antiplatelet therapy reduce cardiovascular events and mortality in patients with diabetes?
This review supports the use of aspirin for cardiovascular prevention and the addition of clopidogrel or GpIIb-IIIa inhibitors for acute coronary syndromes in patients with diabetes.
No takes yet. Share an insight, caveat, or question.
Supports aspirin and adjunctive therapy in diabetic patients; leaves open need for updated RCTs in contemporary settings.
Colwell et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: